Biocartis noted that it has suspended its partnership with Exact Sciences to develop the Idylla IVD Oncotype Dx Breast Recurrence Score test project due to the pandemic.
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.
IVDs in the future will require certification in England, Scotland, and Wales, while companies will still be able to sell tests in Northern Ireland under existing EU regulations.
The funding will be used to start a new trial to assess the benefits of repeat population testing, expand existing trials, and increase PCR-based testing capacity.
Created by BloodPAC members, the resource may serve as a set of generic analytical protocols to help define industry standards for developing liquid biopsy tests.
Google Cloud said that the augmented reality microscope would enable access to artificial intelligence models that can help military doctors with cancer detection.
The Australian molecular diagnostics firm had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with the Nasdaq listing rule.
State agencies will no longer use Quest for testing following its failure to report to the state results from roughly 75,000 SARS-CoV-2 tests in a timely manner.
The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, enabling appropriate treatment options.
